Méningococcie
Effectiveness of Serogroup C Meningococcal Conjugate Vaccine: A 7-Year Follow-up in Quebec, Canada
Background: A mass immunization campaign was implemented in 2001 to control a serogroup C meningococcal disease outbreak, and a newly licensed serogroup C meningococcal conjugate vaccine (C-MCV) was used. In 2002, 1 C-MCV dose was routinely offered to children 12 months of age.
Objective: To assess the epidemiologic effect of the campaign and C-MCV effectiveness during a 7-year period according to age at vaccination and delay since vaccine administration.
Methods: Cases of invasive meningococcal infection reported to public health authorities and the reference laboratory during the period 1990 to 2008 were obtained to calculate year- and age-specific incidence rates. Multiple sources were used to ascertain the immunization status of cases. Immunization registry data were used to estimate age-specific C-MCV uptake rates in different birth cohorts. Vaccine effectiveness was estimated by Mantel-Haenszelmethod and logistic regression models.
Results: After mass immunization campaign, meningococcal C disease incidence decreased markedly not only in highly vaccinated but also in poorly vaccinated and nonvaccinated birth cohorts. Overall vaccine effectiveness was 87.4% (95% CI: 75.4%-94.2%) with lower protection in children vaccinated <2 years of age and waning of protection of higher magnitude in this age group.
Conclusion: Results support the current Canadian recommendation to provide booster vaccination for adolescents.
Advice for consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine
Contains information about the epidemiology of meningococcal disease and the recommended use of vaccines to protect against infection.
Conseil pour considération du vaccin conjugué quadrivalent contre le méningocoque
Contient de l’information au sujet de l’épidémiologie de la maladie à méningocoque et l’utilisation recommandée des vaccins visant à protéger contre l’infection.
Meningococcal serogroup C conjugate vaccination in Canada : How far have we progressed? How far do we have to go?
Summation of the current (2010) meningococcal immunization strategies used in Canada and an estimate of overall vaccine coverage of children and youth. Suggests that a national immunization program would provide greater vaccine coverage and reduce the number of meningococcal infection cases.
Mise à jour des recommandations concernant la méningococcie et la vaccin conjugué contre le méningocoque
Fournit des données à jour concernant la méningococcie et le vaccin quadrivalent conjugué contre le méningocoque actuellement disponible, MenactraMD (Sanofi Pasteur), et renferme des recommandations additionnelles relatives à l'utilisation des vaccins conjugués contre le méningocoque.
Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations
Provides an update with regard to meningococcal disease and the currently available quadrivalent conjugate meningococcal vaccine, Menactra® (sanofi pasteur) and makes additional recommendations for the use of meningococcal conjugate vaccines.
Déclaration sur le vaccin conjugué contre le méningocoque, sérogroupes A, C, Y et W135
Une déclaration d’un comité consultatif de CCNI, qui fait des recommandations relatives à l’utilisation de Menactra, un vaccin qui confère une protection contre les sérogroupes A, C, Y et W135 du méningocoque.
Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135
An Advisory Committee statement from NACI, which makes recommendations about the use of Menactra, a vaccine that provides protection against meningococcal serogroups A, C, Y and W135.